In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting ...

After a delay, the FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately ...

The key opinion leader discusses how criteria for assisted reproductive technology (ART) coverage are established, including stepwise approaches and considerations for mixed protocols, while ...

Jeffrey Dunn, Pharm.D., MBA, discusses how comparison trials for different assisted reproductive technologies (ARTs) are necessary to evaluate their relative efficacy, safety and cost-effectiveness, ...

Gene Therapy Is Ultra-Ultraexpensive. How It Could Be Made Cheaper ...

Samuel Nordberg, PhD, discusses challenges with the definition and identification of TRD in the clinical setting.

Dr. Samuel Nordberg discusses methods for identifying patients in need of an alternative therapy for TRD at the health system level.

Drs Samuel Nordberg, Patricia Ares-Romero, and Martin Rosenzweig share considerations for effective care delivery for patients with TRD.

The Democrats have expanded the program under the Affordable Care Act. Republicans have proposed cuts in federal funding and work requirements.

KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually.